HIV Infections
Conditions
Brief summary
Part A: The purpose of this part of the study is to understand how the body's immune system responds to a new lab-made antibody against HIV. The study is looking to see if the way the antibody is given affects the immune response. The study will also look at whether the antibody is safe to give to people and does not make them too uncomfortable. Part B: The purpose of this part of the study is to understand how the body's immune system responds to lab-made antibodies against HIV when they are given in combination at different doses. The study also wants to see if the way the antibodies are given affects the immune response.
Detailed description
The HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) are conducting this study to test a combination of different antibodies against HIV. HIV is the virus that causes AIDS. Antibodies are made by the body as one way to respond to or fight infection. Researchers can also make antibodies in laboratories and give them to people by infusions into a vein or under the skin. There are 2 parts of this study, Part A and Part B. About 15 people will take part in Part A of this study to test one study antibody. After early safety results from Part A are obtained, a decision will be made as to whether or not to do Part B of the study. Part B of the study would test a combination of 3 antibodies. If it is decided to move forward with Part B, 80 more people will join.
Interventions
DRUGPGT121.414.LS (20mg/kg, SC)
PGT121.414.LS 20mg/kg administered via SC infusion
DRUGPGT121.414.LS (1.4g, IV)
PGT121.414.LS 1.4g administered via IV infusion
DRUGPGT121.414.LS (1.4g, SC)
PGT121.414.LS 1.4g administered via SC infusion
DRUGPGT121.414.LS (40mg/kg, IV)
PGT121.414.LS 40mg/kg administered via IV infusion
DRUGPGDM1400LS (5mg/kg, IV)
5 mg/kg to be administered via IV infusion
DRUGPGDM1400LS (20mg/kg, IV)
20 mg/kg to be administered via IV infusion
DRUGPGDM1400LS (20mg/kg, SC)
20 mg/kg to be administered via SC infusion
DRUGPGDM1400LS (40mg/kg, IV)
40 mg/kg to be administered via IV infusion
DRUGPGDM1400LS (40mg/kg, SC)
40 mg/kg to be administered via SC infusion
DRUGPGDM1400LS (1.4g, IV)
1.4gram to be administered via IV infusion
DRUGPGDM1400LS (1.4g, SC)
1.4gram to be administered via SC infusion
DRUGVRC07-523LS (20mg/kg, IV)
VRC07-523LS 20mg/kg administered via IV infusion
DRUGVRC07-523LS (20mg/kg, SC)
VRC07-523LS 20mg/kg administered via SC infusion
DRUGVRC07-523LS (1.4g, IV)
VRC07-523LS 1.4g administered via IV infusion
DRUGVRC07-523LS (1.4g, SC)
VRC07-523LS 1.4g administered via SC infusion
DRUGVRC07-523LS (40mg/kg, IV)
VRC07-523LS 40mg/kg administered via IV infusion
DRUGPGT121.414.LS (20mg/kg, IV)
PGT121.414.LS 20mg/kg administered via IV infusion
Sponsors
National Institutes of Health (NIH)
Department of Health and Human Services
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age of 18 through 50 years 2. Access to a participating CRS and willingness to be followed for the planned duration of the study 3. Ability and willingness to provide informed consent 4. Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first study product administration with verbal demonstration of understanding of all questionnaire items answered incorrectly 5. Agrees not to enroll in another study of an investigational research agent until completion of the last required protocol clinic visit. 6. Good general health as shown by medical history, physical exam, and screening laboratory tests 7. Willingness to receive HIV test results 8. Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling. 9. Assessed by the clinic staff as being at low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit (see Appendix J and Appendix K). 10. Hemoglobin * ≥ 11.0 g/dL for volunteers who were assigned female sex at birth * ≥ 13.0 g/dL for volunteers who were assigned male sex at birth and transgender males who have been on hormone therapy for more than 6 consecutive months * ≥ 12.0 g/dL for transgender females who have been on hormone therapy for more than 6 consecutive months * For transgender volunteers who have been on hormone therapy for less than 6 consecutive months, determine hemoglobin eligibility based on the sex assigned at birth 11. White blood cell count = 2,500 to 12,000 cells/mm3 12. WBC differential either within institutional normal range or with site clinician approval 13. Platelets = 125,000 to 550,000 cells/mm3 14. Chemistry panel: alanine aminotransferase (ALT) \< 1.25 times the institutional upper limit of normal (ie, \< 1.25 times the reference range upper limit) and creatinine \< 1.1 times the institutional upper limit of normal (ie, \<1.1 times the reference range upper limit) 15. Negative HIV-1 and -2 blood test: US volunteers must have a negative FDA-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA). Non-US sites may use locally available assays that have been approved by HVTN and HPTN Laboratory Operations 16. Negative Hepatitis B surface antigen (HBsAg) 17. Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive 18. Negative or trace urine protein 19. Volunteers who were assigned female sex at birth: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test(s) performed within 48 hours prior to initial study product administration. Persons who are NOT of reproductive potential due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records), are not required to undergo pregnancy testing. 20. A volunteer who was assigned female sex at birth must: * Agree to use effective contraception for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol visit. Effective contraception is defined as using one of the following methods: Condoms (internal and external) with or without a spermicide, Diaphragm or cervical cap with spermicide, Intrauterine device (IUD), Hormonal contraception, Tubal ligation, or Any other contraceptive method approved by the HVTN 140/HPTN 101 PSRT, Successful vasectomy in any partner assigned male sex at birth (considered successful if a volunteer reports that a male partner has \[1\] documentation of azoospermia by microscopy, or \[2\] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy); or, * Not be of reproductive potential, such as having reached menopause (no menses for 1 year) or having undergone hysterectomy or bilateral oophorectomy; or, * Be sexually abstinent. 21. Volunteers who were assigned female sex at birth must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit
Exclusion criteria
1. Weight \< 35kg or \> 115 kg 2. Blood products received within 120 days before first study product administration, unless eligibility for earlier enrollment is determined by the HVTN 140/HPTN 101 PSRT 3. Investigational research agents received within 30 days before first study product administration 4. Intent to participate in another study of an investigational research agent or any other study that requires non-Network HIV antibody testing during the planned duration of the HVTN 140/HPTN 101 study 5. Pregnant or breastfeeding 6. HIV vaccine(s) received in a prior HIV vaccine trial. Volunteers who have received control/placebo in an HIV vaccine trial are not excluded. 7. SARS-CoV-2 vaccine(s) received within 7 days prior to HVTN 140/HPTN 101 enrollment or planned within 7 days after enrollment. 8. Receipt of humanized or human mAbs, whether licensed or investigational. 9. Previous receipt of mAbs VRC01, VRC01LS, VRC07-523LS, PGDM1400, PGT121, PGT121.414.LS. 10. Immunosuppressive medications received within 30 days before first study product administration (Not exclusionary: \[1\] corticosteroid nasal spray; \[2\] inhaled corticosteroids; \[3\] topical corticosteroids for mild, uncomplicated dermatological condition; or \[4\] a single course of oral/parenteral prednisone or equivalent at doses \< 20 mg/day and length of therapy \< 14 days) 11. Serious adverse reactions to PGDM1400LS, VRC07-523LS, or PGT121.414.LS formulation components (see Section 8.2) including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. 12. Immunoglobulin received within 60 days before first study product administration (for mAb see criterion 8 above) 13. Autoimmune disease (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require immunosuppressive medication and that, in the judgment of the CRS investigator, is likely not subject to exacerbation and likely not to complicate Solicited and Unsolicited AE assessments.) 14. Immunodeficiency 15. Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to: * Symptoms consistent with COVID-19 or known SARS-CoV-2 infection, * A process that would affect the immune response, * A process that would require medication that affects the immune response, * Any contraindication to repeated infusions, or blood draws, including inability to establish venous or subcutaneous access, * A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period, * A condition or process (eg, chronic urticaria or recent injection or infusion with evidence of residual inflammation) for which signs or symptoms could be confused with reactions to the study product, or * Any condition specifically listed among the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | Measured during Days 56 and 168* Days with * are only available for T6-T10 | Magnitude breadth of neutralizing activity measured with Env pseudotyped viruses specific for either PGDM1400LS, VRC07-523LS or PGT121.414LS in TZM-bl cells at prespecified timepoints among participants who received all scheduled product administrations for Parts A and B. |
| Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | Measured during Days 0, 0.0417 (1hr post 1st infusion), 3, 6, 28, 56, 112, 112.0417 (1hr post 2nd infusion), 168, 224, and 280 | Serum concentrations of PGT121.414.LS at prespecified timepoints among participants who received all scheduled product administrations |
| Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | Measured during Days 0, 0.0417 (1hr post 1st infusion), 3, 6, 28, 56, 112, 112.0417 (1hr post 2nd infusion), 168, 224, and 280 | Serum concentrations of VRC07-523LS at prespecified timepoints among participants who received all scheduled product administrations |
| Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | Measured during Days 0, 3, 6, 28, 56, 112, 168, 224*, and 280* Days with * are only available for T6-T10 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Measured through Month Measured through 3 days after each vaccine dose at T1-T5: Day 0 and T6-T10: Days 0, 112 | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Measured through Month Measured through 3 days after each vaccine dose at T1-T5: Day 0 and T6-T10: Days 0, 112 | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented |
| Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Measured through Month Measured through 3 days after each vaccine dose at T1-T5: Day 0 and T6-T10: Days 0, 112 | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented |
| Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10 | For each local laboratory measure, summary statistics: median and interquartile range were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Creatinine | Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Hemoglobin | Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10 | The number (percentage) of participants with lab grade \>= 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm |
| Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Measured through Month 4 | The number (percentage) of participants with early discontinuation of vaccinations and reason for discontinuation was summarized by arm |
| Number of Participants With Early Termination of Study and Reason for Early Termination | Measured through Month 6 in Part A and Month 10 in Part B | The number (percentage) of participants with early termination of study and reason for early termination was summarized by arm |
| Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | Measured during Days 0, 0.0417 (1hr post 1st infusion), 3, 6, 28, 56, 112, 112.0417 (1hr post 2nd infusion)*, 168, 224*, and 280* Days with * are only available for T6-T10 | Serum concentrations of PGDM1400LS at prespecified timepoints among participants who received all scheduled product administrations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | Measured during Screening, Days 0, 112*, 168†, and 280* Days with † are only available for T1-T5 Days with * are only available for T6-T10 | Anti-drug Antibodies (ADA) occurrence in each group measured at prespecified timepoints for all participants in all groups regardless of how many product administrations and how much product they received. Tier 2 responses are only generated for participants who had positive responses to Tier 1. |
| Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | Measured during Screening, Days 0, 112*, 168†, and 280* Days with † are only available for T1-T5 Days with * are only available for T6-T10 | Anti-drug Antibodies (ADA) tier 3 titers in each group measured at prespecified timepoints for all participants in all groups regardless of how many product administrations and how much product they received. Tier 3 titers are only available for those participants who had positive for ADA Tiers 1 and 2. |
| Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | Day 56 and Day 168* corresponding to Month 2 and Month 6* of the study. Days with * are only available for T6-T10 | Magnitude of neutralizing activity against a panel of Env-pseudotyped reference viruses that are sensitive to all three bnAbs in TZM-bl cells at selected timepoints for all participants in all groups regardless of how many product administrations and how much product they received |
Countries
Kenya, South Africa, United States, Zimbabwe
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 PGDM1400LS 5 mg/kg to be administered IV at Month 0. | 3 |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 PGDM1400LS 20 mg/kg to be administered IV at Month 0. | 3 |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 PGDM1400LS 20 mg/kg to be administered SC at Month 0. | 3 |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 PGDM1400LS 40 mg/kg to be administered IV at Month 0. | 3 |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 PGDM1400LS 40 mg/kg to be administered SC at Month 0. | 3 |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 PGDM1400LS 20 mg/kg AND VRC07-523LS 20 mg/kg AND PGT121.414LS 20 mg/kg to be administered IV sequentially in this order at Month 0 and Month 4. | 16 |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 PGDM1400LS 20 mg/kg AND VRC07-523LS 20 mg/kg AND PGT121.414LS 20 mg/kg to be administered SC sequentially in this order at Month 0 and Month 4. | 16 |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 PGDM1400LS 1.4 g AND VRC07-523LS 1.4 g AND PGT121.414LS 1.4 g to be administered IV sequentially in this order at Month 0 and Month 4. | 16 |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 PGDM1400LS 1.4 g AND VRC07-523LS 1.4 g AND PGT121.414LS 1.4 g to be administered SC sequentially in this order at Month 0 and Month 4. | 16 |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) PGDM1400LS 40 mg/kg AND VRC07-523LS 40 mg/kg AND PGT121.414LS 40 mg/kg to be administered IV sequentially in this order at Month 0 and Month 4. | 16 |
| Total | 95 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | T1: PGDM1400LS (IV) 5 mg/kg mo 0 | T2: PGDM1400LS (IV) 20 mg/kg mo 0 | T3: PGDM1400LS (SC) 20 mg/kg mo 0 | T4: PGDM1400LS (IV) 40 mg/kg mo 0 | T5: PGDM1400LS (SC) 40 mg/kg mo 0 | T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 36 years | 27 years | 27 years | 26 years | 33 years | 25.5 years | 27.5 years | 25.5 years | 26 years | 31 years | 27 years |
| Age, Customized 18 - 20 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 3 Participants | 3 Participants | 2 Participants | 12 Participants |
| Age, Customized 21 - 30 years | 1 Participants | 3 Participants | 2 Participants | 2 Participants | 1 Participants | 9 Participants | 9 Participants | 7 Participants | 8 Participants | 4 Participants | 46 Participants |
| Age, Customized 31 - 40 years | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 3 Participants | 2 Participants | 2 Participants | 7 Participants | 21 Participants |
| Age, Customized 41 - 50 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 3 Participants | 4 Participants | 3 Participants | 3 Participants | 16 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 2 Participants | 14 Participants | 15 Participants | 15 Participants | 16 Participants | 15 Participants | 89 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 12 Participants | 13 Participants | 11 Participants | 13 Participants | 10 Participants | 60 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 1 Participants | 3 Participants | 2 Participants | 3 Participants | 2 Participants | 4 Participants | 2 Participants | 3 Participants | 2 Participants | 4 Participants | 26 Participants |
| Region of Enrollment Kenya | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 1 Participants | 3 Participants | 0 Participants | 9 Participants |
| Region of Enrollment South Africa | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 8 Participants | 7 Participants | 8 Participants | 6 Participants | 4 Participants | 33 Participants |
| Region of Enrollment USA | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 4 Participants | 3 Participants | 6 Participants | 4 Participants | 6 Participants | 38 Participants |
| Region of Enrollment Zimbabwe | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 1 Participants | 3 Participants | 6 Participants | 15 Participants |
| Sex: Female, Male Female | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 9 Participants | 9 Participants | 9 Participants | 6 Participants | 5 Participants | 48 Participants |
| Sex: Female, Male Male | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 7 Participants | 7 Participants | 7 Participants | 10 Participants | 11 Participants | 47 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 |
| other Total, other adverse events | 2 / 3 | 2 / 3 | 2 / 3 | 1 / 3 | 3 / 3 | 13 / 16 | 15 / 16 | 13 / 16 | 15 / 16 | 12 / 16 |
| serious Total, serious adverse events | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 | 0 / 16 |
Outcome results
Primary
Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
For each local laboratory measure, summary statistics: median and interquartile range were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10
Population: 'Overall Number of Participants Analyzed' represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 16 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 48 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 14 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 40.5 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 16 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 17.5 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 19 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 15 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 62 U/L |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 15 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 16 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 15 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 13 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 16 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 65 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 56 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 16 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 63 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 19 U/L |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 14 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 12 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 19 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 12 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 72 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 15 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 21 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 10 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 21 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 68 U/L |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 73 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 73 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 14 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 20 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 17 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 20 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 20 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 84 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 75 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 17 U/L |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 18 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 78 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 21 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 59 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 14 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 81 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 15 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 21 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 18 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 16 U/L |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 23 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 21 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 19 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 76.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 83.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 16.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 280 | 23 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 112 | 77 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 19.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 18.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 22.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 280 | 22 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 112 | 21 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 77 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 112 | 20.5 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 280 | 73 U/L |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 21 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 13 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 20.5 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 22.5 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 74 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 68.5 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 280 | 78 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 13.5 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 16 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 280 | 21 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 112 | 20 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 13 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 280 | 13.5 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 112 | 72 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 19 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 73.5 U/L |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 112 | 14 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 112 | 18.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 75 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 74.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 112 | 70.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 73 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 280 | 72 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 18 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 16.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 16 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 16 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 112 | 16 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 280 | 14.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 18.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 23.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 280 | 18.5 U/L |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 17 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 17.5 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 14 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 85 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 24 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 25 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 280 | 86.5 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 112 | 18.5 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 84 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 280 | 15.5 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 112 | 84 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 14 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 81.5 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 17 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 280 | 22.5 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 24 U/L |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 112 | 24 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 280 | 17.5 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 112 | 24.5 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 168 | 16.5 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 112 | 16 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 56 | 18 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 168 | 20 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Screening | 15 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 280 | 21 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALT (U/L) -Day 0/Enrollment | 18.5 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 0/Enrollment | 20.5 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 280 | 76 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 168 | 78 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 112 | 76 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 56 | 83 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | ALP (U/L) -Day 0/Enrollment | 72 U/L |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) | AST (U/L) -Day 56 | 21 U/L |
Primary
Chemistry and Hematology Laboratory Measures - Creatinine
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10
Population: 'Overall Number of Participants Analyzed' represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.81 mg/dL |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.77 mg/dL |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.75 mg/dL |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.8 mg/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.79 mg/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.78 mg/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.83 mg/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.78 mg/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.83 mg/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.81 mg/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.81 mg/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.8 mg/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.85 mg/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.94 mg/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.89 mg/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.89 mg/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.81 mg/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.9 mg/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.92 mg/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.82 mg/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 280 | 0.74 mg/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.79 mg/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.8 mg/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.74 mg/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 112 | 0.73 mg/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.73 mg/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.7 mg/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.74 mg/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 112 | 0.74 mg/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 280 | 0.76 mg/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.74 mg/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.72 mg/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.79 mg/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.7 mg/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.74 mg/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.76 mg/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 112 | 0.76 mg/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 280 | 0.81 mg/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.77 mg/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 112 | 0.79 mg/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.79 mg/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.8 mg/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 280 | 0.84 mg/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.81 mg/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 112 | 0.8 mg/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 56 | 0.79 mg/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 280 | 0.78 mg/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 0/Enrollment | 0.82 mg/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Day 168 | 0.81 mg/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Creatinine | Creatinine (mg/dL) -Screening | 0.81 mg/dL |
Primary
Chemistry and Hematology Laboratory Measures - Hemoglobin
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10
Population: 'Overall Number of Participants Analyzed' represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 12.3 g/dL |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 12.5 g/dL |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 13.6 g/dL |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 12.9 g/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 14.3 g/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 14.3 g/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 13.6 g/dL |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 12.3 g/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 13.7 g/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 13 g/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 13.3 g/dL |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 15.1 g/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 13.5 g/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 13.3 g/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 13.9 g/dL |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 12.7 g/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 13.6 g/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 13.5 g/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 14.3 g/dL |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 13.8 g/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 14.5 g/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 14.75 g/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 112 | 14.3 g/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 280 | 13.8 g/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 14.5 g/dL |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 14.75 g/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 13.5 g/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 13.85 g/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 280 | 13.85 g/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 112 | 13.6 g/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 14.05 g/dL |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 13.95 g/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 280 | 13.8 g/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 13.4 g/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 14.1 g/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 112 | 14 g/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 13.85 g/dL |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 13.9 g/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 280 | 13.85 g/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 112 | 14.6 g/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 14.35 g/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 14.8 g/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 14.35 g/dL |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 14.9 g/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 280 | 15.05 g/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 168 | 15.45 g/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 112 | 15 g/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Screening | 15.8 g/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 0/Enrollment | 14.9 g/dL |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Hemoglobin | Hemoglobin (g/dL) -Day 56 | 14.9 g/dL |
Primary
Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10
Population: 'Overall Number of Participants Analyzed' represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 2.76 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 3.44 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 2.88 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 4.3 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 2.81 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 2.68 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 2.32 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 2.88 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 4.87 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 5.36 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 5.2 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 4.66 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 4.7 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 3.6 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 4.16 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 2.8 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 3.68 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 4.28 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 4.81 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 5.53 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 2.65 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 2.66 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 3.35 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 3.5 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 112 | 2.54 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 280 | 2.05 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 2.25 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 112 | 2.54 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 3.48 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 2.87 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 2.8 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 280 | 2.72 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 280 | 3.38 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 3.28 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 3.54 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 112 | 2.84 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 3.39 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 3.01 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 2.72 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 112 | 2.57 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 3.27 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 2.95 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 280 | 3.29 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 2.92 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 168 | 2.77 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 56 | 3.13 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 280 | 2.76 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Screening | 3 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 2.77 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count | Neutrophils (1000 cells/cubic mm) -Day 112 | 2.73 1000 cells/cubic mm |
Primary
Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC)
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10
Population: 'Overall Number of Participants Analyzed' represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 252000 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 213000 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 237000 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 207000 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 5700 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 7100 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5700 1000 cells/cubic mm |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5900 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 5300 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 296000 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5300 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5200 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 4900 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 281000 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 295000 1000 cells/cubic mm |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 304000 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 8500 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 6700 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 288000 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 7600 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 283000 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 289000 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 7900 1000 cells/cubic mm |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 283000 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 7000 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 6300 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 288000 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 6100 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5900 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 324000 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 293000 1000 cells/cubic mm |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 306000 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 399000 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 298000 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 8600 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 6400 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 6700 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 317000 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 294000 1000 cells/cubic mm |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 7200 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 276500 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 280 | 4240 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 6475 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 5335 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 112 | 4880 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 112 | 283500 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 286000 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 282000 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 6045 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 280 | 267000 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 277000 1000 cells/cubic mm |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5000 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 293000 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 6330 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5110 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 112 | 5570 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 285000 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 300500 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 280 | 300000 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5110 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 5425 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 280 | 5385 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 299000 1000 cells/cubic mm |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 112 | 285500 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 6040 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 280000 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 5690 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5285 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 112 | 5210 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 112 | 278500 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 280 | 5550 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5320 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 265500 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 287000 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 280 | 293500 1000 cells/cubic mm |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 265000 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 280 | 296500 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 5575 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 5555 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 298000 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 266000 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 275500 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 280 | 5845 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 112 | 5210 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5120 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 268000 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 112 | 253500 1000 cells/cubic mm |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5255 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 241500 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 112 | 5320 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 56 | 263000 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 5470 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 280 | 248000 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 168 | 251000 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 168 | 5085 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Day 112 | 261000 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 280 | 5025 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Day 56 | 5240 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | WBC (1000 cells/cubic mm) -Screening | 5515 1000 cells/cubic mm |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC) | Platelets (1000 cells/cubic mm) -Screening | 249000 1000 cells/cubic mm |
Primary
Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B
Magnitude breadth of neutralizing activity measured with Env pseudotyped viruses specific for either PGDM1400LS, VRC07-523LS or PGT121.414LS in TZM-bl cells at prespecified timepoints among participants who received all scheduled product administrations for Parts A and B.
Time frame: Measured during Days 56 and 168* Days with * are only available for T6-T10
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed- shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 1.83 log10(titer) |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 1.42 log10(titer) |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 2.35 log10(titer) |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 1.76 log10(titer) |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 2.19 log10(titer) |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 1.60 log10(titer) |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 2.33 log10(titer) |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 1.77 log10(titer) |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 1.81 log10(titer) |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 2.26 log10(titer) |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 168 | 3.57 log10(titer) |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 4.24 log10(titer) |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 168 | 4.17 log10(titer) |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 3.62 log10(titer) |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 3.97 log10(titer) |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 168 | 3.41 log10(titer) |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 3.40 log10(titer) |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 168 | 4.07 log10(titer) |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 168 | 4.36 log10(titer) |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 4.22 log10(titer) |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 168 | 3.71 log10(titer) |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 3.69 log10(titer) |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 4.06 log10(titer) |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 168 | 4.17 log10(titer) |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 3.49 log10(titer) |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 168 | 3.54 log10(titer) |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 168 | 4.42 log10(titer) |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 50 - 56 | 4.50 log10(titer) |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 168 | 3.87 log10(titer) |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude Breadth of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B | 80 - 56 | 3.92 log10(titer) |
Primary
Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for
Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for Parts A and B
Time frame: Measured during Days 0, 3, 6, 28, 56, 112, 168, 224*, and 280* Days with * are only available for T6-T10
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed- shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 1294.45 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 633.13 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 3731.64 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 11526.31 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 24.02 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 19536.62 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 192.85 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 746.39 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 1868.90 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 18004.25 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 2890.20 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 4082.03 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 60315.19 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 32088.99 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 4856.32 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 3477.51 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 18493.04 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 12699.51 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 5386.78 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 86169.30 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 2718.94 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 826.94 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 492.93 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 35352.88 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 5.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 37356.09 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 437.47 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 25318.17 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 5965.47 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 183.14 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 20515.29 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 6240.04 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 1055.97 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 3491.99 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 4108.53 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 5.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 2672.84 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 18546.43 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 38798.72 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 32217.59 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 14157.79 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 4626.30 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 2065.96 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 210641.18 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 190567.11 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 493.97 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 95958.61 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 12.63 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 11.35 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 15403.44 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 3949.41 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 5.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 35905.88 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 6475.97 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 16592.14 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 13.95 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 136086.26 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 48197.90 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 11323.91 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 10784.72 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 104138.90 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 1934.01 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 442.94 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 228540.05 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 1283.49 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 16526.64 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 5.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 5.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 321.65 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 179.90 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 75.92 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 17.74 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 84.51 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 224 | 24.20 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 280 | 22.66 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 4452.10 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 22678.23 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 150.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 224 | 7043.13 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 280 | 1948.28 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 150.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 23888.60 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 14844.38 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 7454.26 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 4039.11 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 1384.65 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 6030.57 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 224 | 1492.16 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 78082.03 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 280 | 504.34 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 150.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 111359.04 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 76729.85 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 42765.16 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 26446.02 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 9790.75 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 36402.30 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 224 | 19975.51 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 280 | 6386.89 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 65735.36 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 150.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 39720.65 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 23276.79 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 11808.90 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 9310.84 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 3115.33 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 14050.60 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 224 | 5670.50 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 5724.38 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 280 | 2210.13 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 32034.53 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 2036.61 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 690.34 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 712.10 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 142.06 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 580.36 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 224 | 112.82 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 280 | 47.06 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 728.14 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 17553.23 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 280 | 2308.80 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 150.00 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 18256.29 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 224 | 4334.66 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 23.96 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 754.64 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 330.68 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 280 | 7614.93 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 2175.54 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 150.00 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 31531.64 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 280 | 1744.59 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 59.59 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 512.34 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5301.73 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 6265.17 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 150.00 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 15139.18 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 1454.65 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 280 | 45.88 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 882.99 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 23502.68 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 10843.79 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 171.01 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 40368.23 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 8557.98 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 10267.77 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 14051.96 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 150.00 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 38090.89 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 224 | 18.20 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 224 | 145.43 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 2222.96 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 29399.28 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 81.67 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 224 | 12846.42 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 280 | 468.48 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 452.05 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 224 | 890.67 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 280 | 15.08 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 3652.50 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 13435.34 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 11401.34 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 82.83 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 8621.43 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 43426.88 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 224 | 4087.73 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 12451.16 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 150.73 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 29.74 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 4132.63 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 53408.16 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 101622.05 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 26799.63 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 22619.87 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 43229.29 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 16750.64 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 63097.95 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 10545.50 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 94187.86 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 150.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 4217.73 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 280 | 626.33 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 224 | 1536.64 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 13643.32 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 4763.95 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 101.47 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 224 | 6640.69 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 17437.11 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 280 | 3869.87 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 1179.07 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 3958.18 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 483.85 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 10272.30 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 14559.28 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 3654.32 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 20973.90 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 2376.08 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 46024.02 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 150.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 150.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 623.34 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 1071.55 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 280 | 2578.49 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 733.53 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 224 | 6044.29 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 21147.90 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 216.97 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 5287.92 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 280 | 18.48 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 207.57 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 398.50 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 224 | 39.01 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 224 | 123.78 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 280 | 67.95 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 74.82 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 27.53 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 280 | 10111.45 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 150.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 224 | 21710.66 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 39562.48 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 30936.66 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 59253.58 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 12309.30 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 42738.95 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 280 | 4586.73 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 5614.97 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 224 | 7348.03 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 12171.52 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 44190.21 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 277.60 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 10878.05 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 76.61 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 280 | 17.11 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 150.00 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 5709.83 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 224 | 28.50 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 15171.56 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 224 | 1375.26 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 13229.33 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 395.85 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 63289.84 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 3491.96 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 15761.35 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 36565.68 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 224 | 262.75 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 280 | 620.44 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 150.00 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 5803.64 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 18368.24 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 280 | 59.54 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 150.00 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 10271.32 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 2816.67 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 64.31 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 3008.78 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 44216.61 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 150.00 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 11285.60 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 31.34 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 280 | 2679.28 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 344.46 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 11379.60 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 280 | 11651.39 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 1138.94 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 40152.25 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 56244.87 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 125.74 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 224 | 5932.23 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 341.19 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 4572.76 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 20066.68 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 465.56 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 224 | 19689.54 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 1245.31 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 21375.24 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 280 | 23.39 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 0 | 150.00 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 3 | 155263.94 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 6 | 130118.65 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 28 | 63877.56 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 56 | 31424.52 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 112 | 7748.86 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 168 | 40924.44 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 224 | 12390.13 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 50 - 280 | 4869.88 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 0 | 150.00 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 3 | 42729.83 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 6 | 34219.06 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 28 | 15821.39 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 56 | 8098.32 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 112 | 1425.73 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 168 | 8816.20 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 224 | 2624.72 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | 6540.v4.c1 - 80 - 280 | 957.91 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 0 | 150.00 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 3 | 174911.25 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 6 | 114514.34 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 28 | 75530.56 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 56 | 58752.83 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 112 | 23825.19 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 168 | 88221.37 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 224 | 37227.47 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 50 - 280 | 15470.09 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 0 | 150.00 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 3 | 56218.55 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 6 | 36881.20 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 28 | 22791.38 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 56 | 18420.21 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 112 | 6910.25 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 168 | 29423.14 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 224 | 13020.14 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CH505TF.N334S.N160A.N280D.1 - 80 - 280 | 5429.12 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 0 | 5.00 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 3 | 7184.43 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 6 | 5362.34 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 28 | 1692.69 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 56 | 1173.82 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 112 | 564.30 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 168 | 803.11 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 224 | 277.69 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 50 - 280 | 130.02 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 0 | 5.00 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 3 | 1590.53 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 6 | 881.45 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 28 | 352.64 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 56 | 162.81 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 112 | 55.81 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 168 | 103.93 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Serum Neutralizing Activity (ie, Neutralizing Antibody Titers, Including ID50, ID80) for | CNE55.N160K - 80 - 224 | 43.58 titer |
Primary
Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC).
The number (percentage) of participants with lab grade \>= 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm
Time frame: Measured during Screening, Days 0, 56, 112*, 168, and 280* Days with * are only available for T6-T10
Population: 'Overall Number of Participants Analyzed' represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 2 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 3 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 2 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 2 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 2 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 2 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 3 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 56 | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 112 | 3 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 168 | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 280 | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALP (U/L) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Creatinine (mg/dL) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 112 | 3 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Platelets (1000 cells/cubic mm) -Day 168 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | ALT (U/L) -Day 56 | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 0/Enrollment | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | AST (U/L) -Day 168 | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Neutrophils (1000 cells/cubic mm) -Day 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | WBC (1000 cells/cubic mm) -Screening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Lymphocytes (1000 cells/cubic mm) -Day 56 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC). | Hemoglobin (g/dL) -Day 0/Enrollment | 0 Participants |
Primary
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
Time frame: Measured through Month Measured through 3 days after each vaccine dose at T1-T5: Day 0 and T6-T10: Days 0, 112
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 2 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 2 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 2 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 2 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 2 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 13 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 12 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 12 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 2 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 10 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 3 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 10 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 5 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 9 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/Redness | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/Swelling | Mild | 0 Participants |
Primary
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
Time frame: Measured through Month Measured through 3 days after each vaccine dose at T1-T5: Day 0 and T6-T10: Days 0, 112
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 2 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 2 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 2 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 15 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 6 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 9 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 13 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 3 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 12 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 3 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 14 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
Primary
Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented
Time frame: Measured through Month Measured through 3 days after each vaccine dose at T1-T5: Day 0 and T6-T10: Days 0, 112
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 2 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 2 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 1 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 1 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 2 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 1 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 2 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 2 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 1 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 1 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 1 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 2 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 2 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 1 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 2 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 2 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 1 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 2 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 3 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 3 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 13 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 9 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 3 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 7 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 12 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 6 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 4 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 5 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 5 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 11 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 4 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 13 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 15 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 16 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 7 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 15 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 12 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 12 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 10 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 6 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 8 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 15 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 7 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 3 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 15 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 10 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 5 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 14 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 15 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 2 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 5 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 2 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 3 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 5 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 4 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 9 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 3 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 13 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 15 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 10 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 12 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 15 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 16 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 15 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 2 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 6 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 3 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 14 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 15 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 3 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 7 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 12 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 8 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 5 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 4 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 12 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 11 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 13 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 3 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 14 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 14 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 14 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 10 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 10 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | None | 15 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 13 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 3 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature | Mild | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 13 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 14 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 4 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Potentially Life-threatening | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized Pruritus | Moderate | 0 Participants |
Primary
Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation
The number (percentage) of participants with early discontinuation of vaccinations and reason for discontinuation was summarized by arm
Time frame: Measured through Month 4
Population: Safety population
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 3 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 13 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 15 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 15 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 14 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unsolicited AE | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited AE | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator reason | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not discontinue SPA | 14 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Lost to Follow-Up | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Withdrawal by Subject | 1 Participants |
Primary
Number of Participants With Early Termination of Study and Reason for Early Termination
The number (percentage) of participants with early termination of study and reason for early termination was summarized by arm
Time frame: Measured through Month 6 in Part A and Month 10 in Part B
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 3 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 3 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 3 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 3 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 3 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 2 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 13 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 16 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 16 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 16 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Termination of Study and Reason for Early Termination | Lost to Follow-Up | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Termination of Study and Reason for Early Termination | Did not terminate Study | 14 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Number of Participants With Early Termination of Study and Reason for Early Termination | Withdrawal by Subject | 1 Participants |
Primary
Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations
Serum concentrations of PGDM1400LS at prespecified timepoints among participants who received all scheduled product administrations
Time frame: Measured during Days 0, 0.0417 (1hr post 1st infusion), 3, 6, 28, 56, 112, 112.0417 (1hr post 2nd infusion)*, 168, 224*, and 280* Days with * are only available for T6-T10
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed- shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 88.87 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 95.69 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 69.81 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 96.49 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 19.24 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 9.26 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 43.02 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 159.59 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 46.08 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 95.78 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 209.91 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 375.39 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 361.09 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 432.62 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 146.40 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 140.04 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 50.75 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 19.19 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 1.19 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 97.86 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 205.63 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 80.29 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 344.23 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 685.85 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 727.44 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 603.62 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 157.13 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 510.53 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 429.97 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 105.81 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 313.98 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 214.17 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 2.92 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 447.90 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 46.78 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 165.77 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 307.89 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112.0417 (Day 112 1 hr post-infusion) | 538.95 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 145.70 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 266.18 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 54.73 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 553.60 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 224 | 62.34 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 280 | 28.91 ug/ml |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 112.02 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 113.85 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 6.38 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 141.12 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 151.45 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 75.03 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 42.29 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112.0417 (Day 112 1 hr post-infusion) | 55.77 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 120.50 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 224 | 57.01 ug/ml |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 280 | 23.87 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 66.50 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 280 | 41.15 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 265.27 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 339.86 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 612.47 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 183.47 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 128.23 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 224 | 71.55 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 161.22 ug/ml |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112.0417 (Day 112 1 hr post-infusion) | 655.22 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 154.89 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 219.97 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 46.32 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112.0417 (Day 112 1 hr post-infusion) | 63.50 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 212.99 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 11.36 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 123.02 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 280 | 32.96 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 224 | 59.31 ug/ml |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 102.92 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 168 | 262.73 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112 | 98.76 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 6 | 499.59 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 3 | 594.72 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 56 | 215.93 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 28 | 304.70 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0.0417 (Day 0 1 hr post-infusion) | 1190.49 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 0 | 0.04 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 112.0417 (Day 112 1 hr post-infusion) | 1347.38 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 280 | 65.37 ug/ml |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Serum Concentration Levels of PGDM1400LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400LS - 224 | 124.27 ug/ml |
Primary
Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations
Serum concentrations of PGT121.414.LS at prespecified timepoints among participants who received all scheduled product administrations
Time frame: Measured during Days 0, 0.0417 (1hr post 1st infusion), 3, 6, 28, 56, 112, 112.0417 (1hr post 2nd infusion), 168, 224, and 280
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed- shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 56 | 148.41 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112 | 87.90 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0 | 0.10 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 168 | 188.24 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 6 | 336.42 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 224 | 104.50 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 280 | 55.87 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 3 | 386.38 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112.0417 (Day 112 1 hr post-infusion) | 651.90 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 28 | 218.67 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0.0417 (Day 0 1 hr post-infusion) | 903.30 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 28 | 155.20 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112 | 58.88 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 56 | 104.16 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0.0417 (Day 0 1 hr post-infusion) | 4.97 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0 | 0.10 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 224 | 96.83 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 3 | 229.12 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 280 | 57.47 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 168 | 171.21 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 6 | 210.82 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112.0417 (Day 112 1 hr post-infusion) | 72.48 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 56 | 174.96 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0 | 0.10 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0.0417 (Day 0 1 hr post-infusion) | 1021.49 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 3 | 431.97 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 6 | 348.90 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 28 | 240.20 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112 | 104.02 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112.0417 (Day 112 1 hr post-infusion) | 831.75 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 168 | 235.47 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 224 | 120.60 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 280 | 75.78 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 6 | 269.04 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0 | 0.10 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0.0417 (Day 0 1 hr post-infusion) | 7.22 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 280 | 57.10 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 224 | 95.66 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 3 | 264.14 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 56 | 144.98 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112.0417 (Day 112 1 hr post-infusion) | 80.52 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 168 | 172.71 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 28 | 199.02 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112 | 72.58 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0 | 0.10 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112 | 159.04 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 6 | 623.84 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 112.0417 (Day 112 1 hr post-infusion) | 1759.82 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 3 | 679.23 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 280 | 111.83 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 168 | 386.92 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 0.0417 (Day 0 1 hr post-infusion) | 1875.25 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 224 | 217.87 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 56 | 275.85 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of PGT121.414LS Among Participants Who Received All Scheduled Product Administrations | PGT121.414.LS - 28 | 398.70 ug/ml |
Primary
Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations
Serum concentrations of VRC07-523LS at prespecified timepoints among participants who received all scheduled product administrations
Time frame: Measured during Days 0, 0.0417 (1hr post 1st infusion), 3, 6, 28, 56, 112, 112.0417 (1hr post 2nd infusion), 168, 224, and 280
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed- shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 56 | 64.22 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112 | 27.81 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0 | 0.02 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 168 | 74.16 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 6 | 221.59 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 224 | 31.52 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 280 | 11.32 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 3 | 302.96 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112.0417 (Day 112 1 hr post-infusion) | 660.51 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 28 | 109.16 ug/ml |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0.0417 (Day 0 1 hr post-infusion) | 663.07 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 28 | 75.29 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112 | 17.58 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 56 | 41.90 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0.0417 (Day 0 1 hr post-infusion) | 4.44 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0 | 0.02 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 224 | 25.14 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 3 | 129.45 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 280 | 9.26 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 168 | 64.42 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 6 | 129.81 ug/ml |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112.0417 (Day 112 1 hr post-infusion) | 22.38 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 56 | 64.04 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0 | 0.02 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0.0417 (Day 0 1 hr post-infusion) | 695.08 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 3 | 324.02 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 6 | 220.64 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 28 | 109.48 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112 | 29.89 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112.0417 (Day 112 1 hr post-infusion) | 671.49 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 168 | 81.72 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 224 | 31.16 ug/ml |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 280 | 12.84 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 6 | 191.63 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0 | 0.02 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0.0417 (Day 0 1 hr post-infusion) | 6.84 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 280 | 10.43 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 224 | 28.68 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 3 | 188.96 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 56 | 58.30 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112.0417 (Day 112 1 hr post-infusion) | 29.32 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 168 | 68.32 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 28 | 98.05 ug/ml |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112 | 21.99 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0 | 0.02 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112 | 41.09 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 6 | 370.32 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 112.0417 (Day 112 1 hr post-infusion) | 1344.90 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 3 | 482.08 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 280 | 17.33 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 168 | 124.88 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 0.0417 (Day 0 1 hr post-infusion) | 1289.22 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 224 | 42.35 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 56 | 103.01 ug/ml |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Serum Concentration Levels of VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS - 28 | 182.31 ug/ml |
Secondary
Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B
Anti-drug Antibodies (ADA) tier 3 titers in each group measured at prespecified timepoints for all participants in all groups regardless of how many product administrations and how much product they received. Tier 3 titers are only available for those participants who had positive for ADA Tiers 1 and 2.
Time frame: Measured during Screening, Days 0, 112*, 168†, and 280* Days with † are only available for T1-T5 Days with * are only available for T6-T10
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed-shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGDM1400LS - Tier 3 - 0 | 1 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGT121.414.LS - Tier 3 - 0 | 9 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGT121.414.LS - Tier 3 - 0 | 3 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGDM1400LS - Tier 3 - 0 | 243 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | VRC07-523LS - Tier 3 - 0 | 15 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGDM1400LS - Tier 3 - 280 | 3 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGDM1400LS - Tier 3 - 0 | 27 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGT121.414.LS - Tier 3 - 0 | 2187 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | VRC07-523LS - Tier 3 - 0 | 1 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGDM1400LS - Tier 3 - 0 | 3 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | VRC07-523LS - Tier 3 - 0 | 1 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGT121.414.LS - Tier 3 - 0 | 1 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | PGT121.414.LS - Tier 3 - 0 | 1 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Anti-drug Antibodies (ADA) Titers for Participants in Parts A and B | VRC07-523LS - Tier 3 - 0 | 1 titer |
Secondary
Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time.
Magnitude of neutralizing activity against a panel of Env-pseudotyped reference viruses that are sensitive to all three bnAbs in TZM-bl cells at selected timepoints for all participants in all groups regardless of how many product administrations and how much product they received
Time frame: Day 56 and Day 168* corresponding to Month 2 and Month 6* of the study. Days with * are only available for T6-T10
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed- shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 42.32 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 7831.73 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 44472.66 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 639.49 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 1208.31 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 52.48 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 2054.33 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 10.00 titer |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 3051.10 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 21.85 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 42634.56 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 8993.79 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 7065.76 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 479.06 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 49.04 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 73.40 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 133.29 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 170780.42 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 147.95 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 141.31 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 10.00 titer |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 82.59 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 53.90 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 1349.82 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 3980.77 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 41897.36 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 13815.72 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 264.99 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 3238.87 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 126.83 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 10.00 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 20.64 titer |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 88.96 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 18366.52 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 29824.76 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 79.78 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 5744.76 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 163.91 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 107823.15 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 278.40 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 26.97 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 796.76 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 10.00 titer |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 5823.93 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 121.63 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 19004.67 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 267.65 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 84.29 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 48.80 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 5206.67 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 120.68 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 77124.52 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 8454.64 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 11331.69 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 70.41 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 10.00 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 481.05 titer |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 10.00 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 168 | 86881.47 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 28867.34 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 168 | 15360.16 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 9199.85 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 168 | 4947.38 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 168357.12 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 41391.40 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 168 | 28897.55 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 33327.66 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 168 | 23924.35 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 10157.60 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 168 | 5888.07 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 6702.06 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 168 | 8055.72 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 1550.43 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 168 | 1681.16 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 39127.87 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 168 | 45487.53 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 10658.64 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 168 | 9737.36 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 1238.90 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 168 | 1047.87 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 357.98 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 168 | 322.12 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 16066.82 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 168 | 22218.02 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 4007.12 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 168 | 3730.92 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 40369.74 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 168 | 31018.25 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 11734.09 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 168 | 10566.71 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 2124.99 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 168 | 1698.60 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 291.52 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 168 | 253.39 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 36426.42 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 168 | 38260.68 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 11959.12 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 168 | 10865.19 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 18072.17 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 168 | 20762.95 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 4856.43 titer |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 168 | 4578.94 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 755.24 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 5333.96 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 844.66 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 1816.41 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 168 | 4998.26 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 168 | 23002.49 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 168 | 11294.94 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 8733.83 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 168 | 2646.71 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 22594.30 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 19116.20 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 168 | 33646.19 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 168 | 10917.47 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 24700.41 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 168 | 31670.23 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 168 | 15632.62 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 2649.77 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 176.65 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 168 | 8441.28 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 168 | 7091.64 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 6762.32 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 168 | 3553.36 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 168 | 252.05 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 543.16 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 168 | 22333.24 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 23445.12 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 168 | 837.65 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 3827.22 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 66253.95 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 168 | 218.16 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 12696.91 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 168 | 3858.60 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 8998.09 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 6686.16 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 3318.05 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 157.57 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 168 | 19437.06 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 168 | 17928.86 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 168 | 995.89 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 168 | 71999.91 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 21151.88 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 168 | 4043.14 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 168 | 1328.75 titer |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 9124.56 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 8684.03 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 1061.53 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 23023.75 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 168 | 1120.53 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 168 | 8771.74 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 365.00 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 168 | 316.37 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 7284.91 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 168 | 6921.19 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 168 | 7070.55 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 17822.44 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 168 | 54853.25 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 168 | 30148.06 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 4663.11 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 168 | 4616.80 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 168 | 26314.31 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 40507.06 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 168 | 46842.83 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 29807.82 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 13241.02 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 168 | 12934.70 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 168 | 39488.60 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 33571.08 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 19418.37 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 1688.12 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 168 | 2019.75 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 168 | 132113.38 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 330.84 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 168 | 348.17 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 107878.92 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 6369.54 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 50167.98 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 168 | 61237.42 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 168 | 5255.50 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 15756.62 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 168 | 16773.85 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 6707.18 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 39373.01 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 168 | 49696.36 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 168 | 1882.14 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 168 | 18239.03 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 11570.84 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 168 | 14323.05 titer |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 1720.99 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 10688.77 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 168 | 1448.31 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 14887.80 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 4266.58 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 168 | 5397.31 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 1368.86 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 168 | 245.61 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 7703.47 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 168 | 33050.62 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 5054.29 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 300.98 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 168 | 867.36 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 168 | 7753.47 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 102278.55 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 168 | 5430.58 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 17665.67 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 168 | 81157.57 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 28888.77 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 168 | 16910.80 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 168 | 18946.53 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 23847.08 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 168 | 3735.43 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 168 | 8126.62 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 27489.85 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 921.85 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 168 | 27190.76 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 168 | 1683.91 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 23789.32 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 45781.87 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 168 | 2649.60 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 4460.89 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 168 | 26000.40 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 168 | 287.66 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 168 | 18777.41 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 1147.58 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 7957.70 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 168 | 22870.26 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 13043.79 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 157.47 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 168 | 11090.80 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 168 | 10396.23 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 168 | 3885.02 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 5429.73 titer |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 2628.16 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 56 | 29487.53 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 168 | 14806.94 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 168 | 77026.80 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 56 | 2690.94 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 56 | 15033.13 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 50 - 56 | 11642.31 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 50 - 168 | 2596.69 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 168 | 33836.22 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 168 | 148145.98 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 168 | 3200.56 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 50 - 56 | 32917.33 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 56 | 416.93 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 168 | 20457.55 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1180_070EsN - 80 - 168 | 399.61 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 50 - 56 | 256420.14 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 80 - 168 | 9955.22 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 168 | 8034.77 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2805_080Es - 80 - 56 | 2766.88 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 168 | 581.13 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 168 | 1932.03 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 56 | 106157.59 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 50 - 168 | 108220.51 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 56 | 35536.25 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 80 - 56 | 9751.86 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 56 | 10429.26 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 80 - 56 | 488.52 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 80 - 56 | 20826.12 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 56 | 29557.51 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 80 - 168 | 14169.87 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1528_240_RE_pblib_001_s - 80 - 168 | 29248.76 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0445_180_RE_con_s - 50 - 56 | 1798.57 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 56 | 57599.35 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_1535_030sN - 50 - 168 | 45959.19 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_0472_030s - 50 - 168 | 20497.50 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 56 | 76855.39 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2304_150_RE_cs - 50 - 168 | 39775.62 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 168 | 5920.02 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 50 - 168 | 85799.88 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 168 | 58317.53 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H703_2117_110_RE_e2A10s - 80 - 56 | 64290.02 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0128_220_RE_pb001_s - 50 - 56 | 80954.57 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 56 | 24924.38 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0855_080_EsN - 80 - 56 | 7924.07 titer |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Magnitude of Neutralizing Activity Against Env-pseudotyped Viruses in TZM-bl Cells for Part A and B and Clinical Product Assayed at Same Time. | H704_0907_130sN - 80 - 168 | 31529.07 titer |
Secondary
Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B
Anti-drug Antibodies (ADA) occurrence in each group measured at prespecified timepoints for all participants in all groups regardless of how many product administrations and how much product they received. Tier 2 responses are only generated for participants who had positive responses to Tier 1.
Time frame: Measured during Screening, Days 0, 112*, 168†, and 280* Days with † are only available for T1-T5 Days with * are only available for T6-T10
Population: Overall Number of Participants Analyzed represents the number of enrolled participants. Number Analyzed-shows the number of participants with available data after filtering for assay specific quality control criteria at each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 0 Participants |
| T1: PGDM1400LS (IV) 5 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 168 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 0 Participants |
| T2: PGDM1400LS (IV) 20 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 168 | 0 Participants |
| T3: PGDM1400LS (SC) 20 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 168 | 0 Participants |
| T4: PGDM1400LS (IV) 40 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 0 Participants |
| T5: PGDM1400LS (SC) 40 mg/kg mo 0 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 168 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 2 - 0 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 0 | 5 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 0 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 112 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 280 | 0 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 2 - 0 | 1 Participants |
| T6: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 0 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 0 | 3 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 0 | 2 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 2 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 280 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 2 - 0 | 3 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 2 - 280 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 280 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 112 | 0 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 112 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 2 - 0 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 2 - 280 | 1 Participants |
| T7: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 2 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 0 | 6 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 2 - 0 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 0 | 3 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 280 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 2 - 0 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 0 | 3 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 112 | 0 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 280 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 0 | 1 Participants |
| T8: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 280 | 2 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 0 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 0 | 4 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 0 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 2 - 0 | 1 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 112 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 280 | 0 Participants |
| T9: PGDM1400LS + VRC07-523LS + PGT121.414LS (SC) 1 | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 2 - 0 | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 2 - 0 | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 0 | 3 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 0 | 2 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 2 - 0 | 1 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 112 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | VRC07-523LS - Tier 1 - 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGDM1400LS - Tier 1 - 0 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 280 | 0 Participants |
| T10: PGDM1400LS + VRC07-523LS + PGT121.414LS (IV) | Occurrence of Anti-drug Antibodies (ADA) for Participants in Parts A and B | PGT121.414.LS - Tier 1 - 112 | 0 Participants |